+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A pilot study evaluating interleukin-2-activated hematopoietic stem cell transplantation for hematologic malignancies



A pilot study evaluating interleukin-2-activated hematopoietic stem cell transplantation for hematologic malignancies



Journal of HematoTherapy 6(5): 457-464



Cytotoxic effector cells are generated when autologous hematopoietic cells (HSC) are cultured with IL-2 for 24 h. Infusion of these cells followed by IL-2 administration may moderate a graft-versus tumor (GvT) effect in vivo. Sixteen patients--7 with non-Hodgkin's lymphoma (NHL), 2 with AML, 4 with multiple myeloma (MM), and 3 with Hodgkin's disease (HD)--received busulfan (4 mg/kg/day for 4 days) and cyclophosphamide (60 mg/kg/day for 2 days) or cyclophosphamide/TBI (1320 cGy). Autologous HSC were activated by culturing with IL-2 for 24 h before reinfusion. Subcutaneous administration of IL-2 began after engraftment at 1.8 x 10(6) IU/m2/day for 1-4 weeks. Neutrophil engraftment occurred on day 13.1 (median) (range 9-45 days), and platelet engraftment occurred on day 19.3 (median) (range 7-54 days) for 15 patients, with delayed engraftment observed in 3 patients. One patient experienced a fatal cardiac arrhythmia. Five patients developed transient skin rashes with histologic evaluation demonstrating findings consistent with GvHD. At 17 months (median) (range 7-23 months), 9 patients are alive, with 6 patients remaining disease free. This pilot trial demonstrates mild to moderate toxicities and a possible delay in platelet engraftment. Further trials will determine the optimal dose and duration of IL-2 therapy and possible impact of this therapy on survival. Laboratory investigations are evaluating the presence of autologous GvHD and a possible GvT effect.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 045093308

Download citation: RISBibTeXText

PMID: 9368182

DOI: 10.1089/scd.1.1997.6.457


Related references

Allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning regimen for elderly patients (60 years and older) with hematologic malignancies using unrelated donors: a retrospective study from the French society for stem cell transplantation (SFGM-TC). Haematologica 101(6): E262-E265, 2016

Comparison of the outcomes following conventional hematopoietic stem cell transplantation vs reduced-intensity stem cell transplantation in older patients with hematologic malignancies. Blood 102(11): 732a, 2003

Allogeneic hematopoietic stem cell transplantation following donor CIK cell infusion: A phase I study in patients with relapsed/refractory hematologic malignancies. Leukemia Research 48: 6, 2016

A pilot study of allogeneic CD34+ peripheral blood stem cell transplantation in patients with advanced hematologic malignancies. Journal of Investigative Medicine 45(7): 334A, 1997

Relapsing hematologic malignancies after haploidentical hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation 17(8): 1099-1111, 2011

Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 15(4): 1608-1616, 1997

Second allogeneic hematopoietic stem cell transplantation in hematologic malignancies in children: long-term results of a multicenter study of the Spanish Working Party for Bone Marrow Transplantation in Children (GETMON). Haematologica 87(3): 331-332, 2002

Role of second hematopoietic stem cell transplantation in relapsed or refractory hematologic malignancies. Transplantation Proceedings 42(8): 3225-3227, 2010

The role of telomeres and telomerase in hematologic malignancies and hematopoietic stem cell transplantation. Journal of Hematology and Oncology 7: 61, 2014

Non-myeloablative therapy and allogeneic hematopoietic stem cell transplantation in hematologic malignancies. Polskie Archiwum Medycyny Wewnetrznej 105 Suppl: 173-175, 2001

Nutritional and metabolic support in hematologic malignancies and hematopoietic stem cell transplantation. Clinical nutrition: 226-237, 2005

The use of second allogeneic hematopoietic stem cell transplantation for hematologic malignancies relapsed after the first: Does it worth to do?. Transfusion and Apheresis Science 54(1): 91-98, 2016

Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation 12(5): 511-517, 2006

A pilot study of allogenic CD34+ peripheral blood stem cell transplantation using mismatched related donors for patients with advanced hematologic malignancies. Blood 90(10 Suppl. 1 Part 1): 110A, 1997

The outcomes of family haploidentical hematopoietic stem cell transplantation in hematologic malignancies are not associated with patient age. Biology of Blood and Marrow Transplantation 17(8): 1205-1213, 2011